Since there are many pharmacological agents available that target purinergic receptors in a specific manner, in vivo studies aimed at understanding the impact of purinergic receptor signaling in viral encephalitis have the potential to deliver  treatments for better outcomes of encephalitis. This evidence concerns the gene P2RY1 and viral encephalitis.